ModifiedCignaPolicy N/A

Immunologicals - Dupixent

Defines coverage guidance for Dupixent (dupilumab subcutaneous injection) across multiple indications and describes evidentiary and guideline context for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyImmunologicals - Dupixent (coverage criteria for Dupixent/dupilumab)

Policy CodePolicy N/A

Change TypeMaterial updates to indications and authorization durations

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document trials of required standard therapies and specialist involvement before requesting Dupixent.

SourceLink

POLICY UPDATE CHANGES

Authorization durations were updated (initial therapy duration changes for atopic dermatitis and other adjustments).

New indications and criteria were added, including COPD, Chronic Spontaneous Urticaria, Bullous Pemphigoid, Allergic Fungal Rhinosinusitis, and Peanut Allergy listed as not covered.

Eosinophil requirement for asthma clarified to ≥ 150 cells/μL within previous 6 weeks or prior to monoclonal antibody use that may alter eosinophils.

Policy name updated from 'Dupilumab' to 'Immunologicals - Dupixent.'

≥9indications described

12–52wefficacy timepoints

≥300COPD eosinophil threshold

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

6 monthstypical initial approval

1 yearrenewal duration (current therapy)

Coverage Criteria and Indication-Specific Requirements

Covered indications with trial-based prerequisites

Coverage is governed by indication-specific clinical evidence and prior therapy expectations as observed in pivotal trials and guidelines

Indication and evidence: Dupixent is indicated for AFRS (≥6 years with history of sino-nasal surgery), asthma (≥6 years with moderate-to-severe eosinophilic phenotype or OCS-dependent), atopic dermatitis (≥6 months moderate-to-severe not controlled with topical therapy), bullous pemphigoid (≥18 years), COPD (≥18 years with eosinophilic phenotype and inadequate control), CRSwNP (≥12 years with inadequately controlled disease), chronic spontaneous urticaria (≥12 years symptomatic despite H1 antihistamines), eosinophilic esophagitis (≥1 year and ≥15 kg with biopsy-confirmed disease unresponsive to an 8-week high-dose PPI), and prurigo nodularis (≥18 years) as described in pivotal trials and approvals.

Indication-specific age and prior therapy requirements summarized from overview and trial enrollment criteria.

Stepwise therapy expectations

Guideline-aligned prerequisites before biologic therapy

Prior standard therapy: For atopic dermatitis, optimize topical therapies and basic management (moisturizers, bathing modifications) before systemic biologic therapy. For CRSwNP, use intranasal corticosteroids for ≥4 weeks and consider surgery; biologics may be preferred if high disease burden persists despite intranasal corticosteroid therapy. For chronic spontaneous urticaria, trial of second-generation H1-antihistamines with dose escalation up to 4× the FDA dose is recommended before escalation to biologic therapy.intranasal corticosteroid ≥4 weeks; up to 4× H1 dose

Guideline recommendations indicate stepwise approach prior to biologic initiation.

Allergic Fungal Rhinosinusitis